Cargando…
Intravesical therapy for urothelial carcinoma of the bladder
Transurethral resection is an effective therapy for non-muscle-invasive bladder cancer. However, the high rates of recurrence and significant risk of progression in higher grade tumors mandates additional therapy with intravesical agents. In this review we discuss the role of various intravesical ag...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Medknow Publications
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142838/ https://www.ncbi.nlm.nih.gov/pubmed/21814318 http://dx.doi.org/10.4103/0970-1591.82846 |
| _version_ | 1782208866059026432 |
|---|---|
| author | Manoharan, M. |
| author_facet | Manoharan, M. |
| author_sort | Manoharan, M. |
| collection | PubMed |
| description | Transurethral resection is an effective therapy for non-muscle-invasive bladder cancer. However, the high rates of recurrence and significant risk of progression in higher grade tumors mandates additional therapy with intravesical agents. In this review we discuss the role of various intravesical agents currently in use including the immunomodualtory agent BCG and chemotherapeutic agents. We discuss the current guidelines and the role of these therapeutic agents in the context of higher grade Ta and T1 tumors. |
| format | Online Article Text |
| id | pubmed-3142838 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2011 |
| publisher | Medknow Publications |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-31428382011-08-03 Intravesical therapy for urothelial carcinoma of the bladder Manoharan, M. Indian J Urol Symposium Transurethral resection is an effective therapy for non-muscle-invasive bladder cancer. However, the high rates of recurrence and significant risk of progression in higher grade tumors mandates additional therapy with intravesical agents. In this review we discuss the role of various intravesical agents currently in use including the immunomodualtory agent BCG and chemotherapeutic agents. We discuss the current guidelines and the role of these therapeutic agents in the context of higher grade Ta and T1 tumors. Medknow Publications 2011 /pmc/articles/PMC3142838/ /pubmed/21814318 http://dx.doi.org/10.4103/0970-1591.82846 Text en © Indian Journal of Urology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Symposium Manoharan, M. Intravesical therapy for urothelial carcinoma of the bladder |
| title | Intravesical therapy for urothelial carcinoma of the bladder |
| title_full | Intravesical therapy for urothelial carcinoma of the bladder |
| title_fullStr | Intravesical therapy for urothelial carcinoma of the bladder |
| title_full_unstemmed | Intravesical therapy for urothelial carcinoma of the bladder |
| title_short | Intravesical therapy for urothelial carcinoma of the bladder |
| title_sort | intravesical therapy for urothelial carcinoma of the bladder |
| topic | Symposium |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142838/ https://www.ncbi.nlm.nih.gov/pubmed/21814318 http://dx.doi.org/10.4103/0970-1591.82846 |
| work_keys_str_mv | AT manoharanm intravesicaltherapyforurothelialcarcinomaofthebladder |